Lower extremity arterial calcific lesions are a pain point in the clinical treatment of PAD. These lesions often involve the intima and media of arteries, commonly seen in the femoral-popliteal artery and the three branches of the calf arteries with atherosclerotic changes, and are often the most difficult areas to dilate during balloon expansion. Intravascular lithotripsy (IVL) is a new technology whose working principle differs from traditional methods for treating calcified lesions. It uses low-pressure balloon dilation to deliver non-focused pulsed acoustic pressure waves into the lesion, breaking up calcified plaques in the vessel wall.

DEEPQUAKE™, as one of the first domestically produced peripheral vascular intravascular shockwave systems to be launched in China,The application of IVL technology on intimal and medial arterial calcification has demonstrated good efficacy and safety in clinical studies. The product offers a high pulse energy, multiple electrode arrangements, and a variety of balloon lengths, providing more treatment options. It can be used for the pretreatment and balloon dilation of calcified lesions (vascular stenosis ≥50%) in the iliac, femoral, iliofemoral, popliteal, renal, and infrapopliteal arteries of adult patients.

Trulive's DEEPQUAKE™ Peripheral Intravascular Shockwave System is a significant achievement in the localization of intravascular shockwave technology in China.The approval and market launch of this product will further advance the localization process of products in the field of vascular calcification interventional treatment, expanding and fulfilling the treatment options for a large number of patients with vascular calcification. In the future, Trulive will continue to innovate and develop, constantly providing more safe and effective innovative solutions for patients with cardiovascular diseases, allowing "Chinese wisdom" to serve the world!